RAN-MEMANTINE TABLET

Pajjiż: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

MEMANTINE HYDROCHLORIDE

Disponibbli minn:

RANBAXY PHARMACEUTICALS CANADA INC.

Kodiċi ATC:

N06DX01

INN (Isem Internazzjonali):

MEMANTINE

Dożaġġ:

10MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

MEMANTINE HYDROCHLORIDE 10MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

30/100

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0150423001; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2014-02-27

Karatteristiċi tal-prodott

1
PRODUCT MONOGRAPH
Pr
RAN
™
-MEMANTINE
Memantine Hydrochloride Tablets
10 mg
N-methyl-D-aspartate (NMDA) receptor antagonist
Ranbaxy Pharmaceuticals Canada Inc.,
2680 Matheson Blvd. E., Suite 200
Mississauga, Ontario
L4W 0A5
Date of revision:
July 24, 2015
Control No. 186301
RAN trademark owned by Sun Pharmaceutical Industries Ltd.
2
NAME OF DRUG
Pr
RAN
™
-MEMANTINE
Memantine Hydrochloride Tablets
10 mg
THERAPEUTIC CLASSIFICATION
N-methyl-D-aspartate (NMDA) receptor antagonist
ACTION AND CLINICAL PHARMACOLOGY
Persistent activation of the central nervous system
N-methyl-D-aspartate (NMDA) receptors by
the excitatory amino acid glutamate has been hypothesized to
contribute to the symptomatology
of Alzheimer’s disease. Memantine is postulated to exert its
therapeutic effect through its action
as a low to moderate affinity uncompetitive (open channel) NMDA
receptor antagonist, which
binds preferentially to the NMDA receptor-operated cation channels. It
blocks the effects of
pathologically elevated sustained levels of glutamate that may lead to
neuronal dysfunction.
There is no clinical evidence that memantine prevents or slows
neurodegeneration or alters the
course of the underlying dementing process in patients with
Alzheimer’s disease. Memantine
exhibits low to negligible affinity for other receptors (GABA,
benzodiazepine, dopamine,
adrenergic, noradrenergic, histamine and glycine) or voltage-dependent
Ca
2+
, Na
+
or K
+
channels. In addition, it does not directly affect the acetylcholine
receptor or cholinergic
transmission, which have been implicated in the cholinomimetic side
effects (e.g., increased
gastric acid secretion, nausea and vomiting) seen with
acetylcholinesterase inhibitors.
Memantine showed antagonist effects at the 5HT
3
receptor with a potency similar to that for the
NMDA receptor.
In vitro studies have shown that memantine does not affect the
reversible inhibition of
acetylcholinesterase by donepezil or galantamine.
PHARMACOKINETICS
ABSORPTION
Orally administered memantine is completely